Cargando…
Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a c...
Autores principales: | Leonardo-Sousa, Carlota, Carvalho, Andreia Neves, Guedes, Romina A., Fernandes, Pedro M. P., Aniceto, Natália, Salvador, Jorge A. R., Gama, Maria João, Guedes, Rita C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000344/ https://www.ncbi.nlm.nih.gov/pubmed/35408601 http://dx.doi.org/10.3390/molecules27072201 |
Ejemplares similares
-
Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design
por: Guedes, Romina A., et al.
Publicado: (2019) -
New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies
por: Guedes, Romina A., et al.
Publicado: (2023) -
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
por: Guedes, Romina A., et al.
Publicado: (2016) -
Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma
por: Estrada, Filipe G. A., et al.
Publicado: (2021) -
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)